The prognostic value of peripheral blood inflammatory indices early variation in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with nivolumab (Δ-Meet-URO analysis). This is an ...
The company is transitioning through a merger with Monroe Capital Corporation (MRCC), which was delayed to early 2026 due to a fourth-quarter government shutdown. Management expects the merger to ...
CHICAGO (AP) — CHICAGO (AP) — Monroe Capital Corporation (MRCC) on Thursday reported a loss of $2.6 million in its fourth quarter. The Chicago-based company said it had a loss of 12 cents per share.
Results are consistent with the authors' prior findings on the possible effects of circadian rhythm on outcomes after immunotherapy. Patients who received at least 20% of their immunotherapy ...
Horizon Technology Finance Corporation (NASDAQ: HRZN) ("Horizon") (the "Company"), an affiliate of Monroe Capital, announced today that its board of directors has declared monthly cash distributions ...
Baseline neutrophil-to-eosinophil ratio (NER) and its association with clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (CPI). This ...
Trend mirrors move to targeted therapy era. Researchers who studied apopulation-based cohort of patientswith metastatic renal cell carcinoma (mRCC) found a trend towardimproved survival with the shift ...
Maintenance Bavencio with Inlyta interruption is feasible in mRCC, showing promising PFS and OS rates at 31.7 months follow-up. Patients interrupting Inlyta at week 36 had a 24-month PFS rate of 58% ...
Welcome to Monroe Capital Corporation's Third Quarter 2024 Earnings Conference Call. Before we begin, I would like to take a moment to remind our listeners that remarks made during this call today may ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results